Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Transperanceon Jan 05, 2023 10:20am
293 Views
Post# 35204646

Is Sirona a strong buy or a scam?

Is Sirona a strong buy or a scam?When I made my investment in this company many years ago, my assessment was that the 1067 deal would be the ten-bagger, lifting the share-price. I looked forward to the closure of the 1067-deal for so many years. With great patience. Looking at how the company have been managed over the years, I am truly disappointed.

Today, I have many concerns. Are the statements from the company established out of incompetence or are management deliberately deceptive?

As mentioned earlier, the statements out of the June 15, 2022 News Release are not complied with.

But there are also a number of company statements provided earlier that have not been complied with.

For the shareholders, no visible business value has been created by management. The share price is trading at history lows and still, management is providing themselves with options, diluting the value of our holdings. This is a greedy behaviour when no visible business value is created to the shareholders from management. A successful management may grant themselves options, but not an unsuccessful one.  

Why are we not provided with figures from the 1067-deal? Other Biotech companies that enter into deals with Abbvie and other Majors make the financial figures public, so why not Sirona?

Well, maybe it was agreed that a minor part of the up-front payment was to be transferred to Sirona and the major part of the up-front payment be transferred to the personal account of the CEO? My view is that HV, as founder, chairman and CEO, views himself very much as the Sirona alter ego.

Once again, strong buy or scam? At this point, I really don’t know.

In Europe, the shareholders are a prioritised stakeholder that are informed at all time, by this company, not so much. Why do the Sirona hold the figures to themselves? What are management ashamed of?

<< Previous
Bullboard Posts
Next >>